163 related articles for article (PubMed ID: 26989119)
21. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
23. Age-related CXC chemokine receptor-4-deficiency impairs osteogenic differentiation potency of mouse bone marrow mesenchymal stromal stem cells.
Guang LG; Boskey AL; Zhu W
Int J Biochem Cell Biol; 2013 Aug; 45(8):1813-20. PubMed ID: 23742988
[TBL] [Abstract][Full Text] [Related]
24. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
25. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
26. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Fisher WD; Eriksson BI; Bauer KA; Borris L; Dahl OE; Gent M; Haas S; Homering M; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Thromb Haemost; 2007 Jun; 97(6):931-7. PubMed ID: 17549294
[TBL] [Abstract][Full Text] [Related]
29. Bone Morphogenetic Protein 2 Alters Osteogenesis and Anti-Inflammatory Profiles of Mesenchymal Stem Cells Induced by Microtextured Titanium In Vitro.
Hyzy SL; Olivares-Navarrete R; Ortman S; Boyan BD; Schwartz Z
Tissue Eng Part A; 2017 Oct; 23(19-20):1132-1141. PubMed ID: 28351289
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
31. 3,5-dicaffeoyl‑epi-quinic acid from Atriplex gmelinii enhances the osteoblast differentiation of bone marrow-derived human mesenchymal stromal cells via WnT/BMP signaling and suppresses adipocyte differentiation via AMPK activation.
Karadeniz F; Oh JH; Lee JI; Seo Y; Kong CS
Phytomedicine; 2020 Jun; 71():153225. PubMed ID: 32464299
[TBL] [Abstract][Full Text] [Related]
32. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Eriksson BI; Rosencher N; Friedman RJ; Homering M; Dahl OE
Thromb Res; 2012 Aug; 130(2):147-51. PubMed ID: 22225858
[TBL] [Abstract][Full Text] [Related]
33. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
[TBL] [Abstract][Full Text] [Related]
34. Co-culture of the bone and bone marrow: a novel way to obtain mesenchymal stem cells with enhanced osteogenic ability for fracture healing in SD rats.
Zhu C; Sha M; Jiang H; Lin J; Lin W; Li W; Chen X; Huang G; Ding Z
J Orthop Surg Res; 2019 Sep; 14(1):293. PubMed ID: 31481070
[TBL] [Abstract][Full Text] [Related]
35. Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism: Initial Experience in a Single Center.
Wolosker N; Varella AY; Fukuda JM; Teivelis M; Kuzniec S; Krutman M; Guerra JC; Ramacciotti E
Clin Appl Thromb Hemost; 2016 May; 22(4):377-80. PubMed ID: 26739543
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
[TBL] [Abstract][Full Text] [Related]
37. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of human hair follicle dermal sheath mesenchymal stromal cells and their potential in enhancing diabetic wound healing.
Ma D; Kua JE; Lim WK; Lee ST; Chua AW
Cytotherapy; 2015 Aug; 17(8):1036-51. PubMed ID: 25981558
[TBL] [Abstract][Full Text] [Related]
39. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Diamantopoulos A; Lees M; Wells PS; Forster F; Ananthapavan J; McDonald H
Thromb Haemost; 2010 Oct; 104(4):760-70. PubMed ID: 20806107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
